Booming Moderna expands HQ in Cambridge, MA; Vertex maps regulatory timeline for CF combo;

@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech

@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce

@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce

@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce

> Armed with a major league partnership with AstraZeneca ($AZN) and a new $25 million grant from DARPA, a booming Moderna Therapeutics has expanded its headquarters in Cambridge, MA, as it builds a staff of 100 by the end of this year. Release

> In an update out today, Vertex ($VRTX) reports that it expects to see Phase III data for its Kalydeco/VX-809 combo for cystic fibrosis in mid-2014 and plans to file for an approval soon after in the U.S. and Europe. Both drugs have been tapped as "breakthrough" therapies by the FDA. Release

> Actelion ($ATLN) reported rising sales of Tracleer as regulators get closer to an expected approval of the next-gen PAH therapy Opsumit. A decision from the FDA is due this week. Story

Medical Device News

@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev

@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce

@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future  delivery. Article | Follow @MichaelGFierce

> Roche will close 454 Life Sciences and stop making its gene sequencing tech. Item

> Wright buying implant outfit for $80M with eye on Europe. News

> Quest blames outside factors for lowering already diminished 2013 expectations. More

> Device tax repeal fight fails again as government funding bill avoids the issue. Article

Pharma News

@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma

@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce

> FDA experts vote against expansion of Amarin's Vascepa. News

> Pharma dealmakers, listen up: Ireland may close a popular tax loophole. Story

> Roche CEO scuttles Novartis merger talk. More

Pharma Manufacturing News

@EricPFierce: Another gut check for Amarin and its fish oil drug  panel votes against wider use. News | Follow @EricPFierce

> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report

> Federal case over drug shortage comes to an end. Story

> Teva reconsiders production cuts in Israel. Item

> B. Braun recalls product after organic particulate found. More

> Genzyme expanding U.S. plant opened last year. Article

Vaccines News

> Cost of rabies vaccine limiting use in Africa. Report

> Merck, Sanofi report on first vaccine in European pilot project. More

> IOM releases modeling software for vaccine prioritization. Item

> Novartis cuts jobs in California as eastward shift continues. More

> India to expand use of pentavalent vaccine after safety thumbs-up. Article

> U.K. court orders sisters to receive MMR vaccine. Story

And Finally... H7N9 avian flu has resurged. Item

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.